tiprankstipranks
Calithera Bio (CALA)
OTHER OTC:CALA
US Market

Calithera Bio (CALA) Income Statement

449 Followers

Calithera Bio Income Statement

Last quarter (Q4 2022), Calithera Bio's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Calithera Bio's net income was $-6.94M. See Calithera Bio’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
--$ 9.75M$ 0.00$ 0.00$ 22.25M
Cost of Revenue
------
Gross Profit
--$ 9.75M---
Operating Expense
$ 23.02M$ 42.07M$ 125.21M$ 91.39M$ 92.89M$ 79.53M
Operating Income
$ -42.07M$ -42.07M$ -115.46M$ -91.39M$ -92.89M$ -57.28M
Net Non Operating Interest Income Expense
$ 300.00K$ 477.00K$ 345.00K$ 1.25M$ 3.04M$ 2.65M
Other Income Expense
$ 2.34M$ -1.95M----
Pretax Income
$ -39.65M$ -39.65M$ -115.11M$ -90.14M$ -89.86M$ -54.63M
Tax Provision
--$ 0.00---
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -22.65M$ -21.29M$ -115.11M$ -90.14M$ -89.86M$ -54.63M
Basic EPS
$ -5.41$ -4.60$ -31.20$ -1.31$ -1.90$ -1.49
Diluted EPS
$ -8.47$ -7.94$ -31.20$ -1.31$ -1.90$ -1.49
Basic Average Shares
$ 18.53M$ 4.63M$ 3.69M$ 68.81M$ 47.31M$ 36.60M
Diluted Average Shares
$ 19.97M$ 4.99M$ 3.69M$ 68.81M$ 47.31M$ 36.60M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 23.02M$ 42.07M$ 125.21M$ 91.39M$ 92.89M$ 79.53M
Net Income From Continuing And Discontinued Operation
$ -39.69M$ -39.65M$ -115.11M$ -90.14M$ -89.86M$ -54.63M
Normalized Income
$ -30.92M$ -31.32M-$ -90.14M$ -89.86M$ -54.63M
Interest Expense
$ 9.00K-----
EBIT
$ -40.59M$ -39.65M$ -115.11M$ -91.39M$ -92.89M$ -57.28M
EBITDA
$ -40.33M$ -39.40M$ -114.83M$ -91.02M$ -92.42M$ -56.78M
Currency in USD

Calithera Bio Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis